CA-MICROVENTION
MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, announced the publication of the SOFIA™ Aspiration System as first-line Technique (SOFAST): A prospective, multicenter study to assess the efficacy and safety of the 6 French SOFIA™ Flow Plus Aspiration Catheter for endovascular stroke thrombectomy, recently published in the Journal of NeuroInterventional Surgery (JNIS).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709802645/en/
MicroVention Announces Clinical Publication of SOFAST: SOFIA™ Aspiration System as First Line Technique in Treating Acute Ischemic Stroke (Graphic: Business Wire)
The SOFAST study assessed the SOFIA™ Flow Plus Aspiration Catheter (SOFIA 6F) for treating acute ischemic stroke caused by large vessel occlusion. This U.S. Prospective, multicenter study involved 108 patients and aimed to confirm the catheter’s safety, speed and effectiveness in revascularization. The long-standing legacy of SOFIA is reinforced by the important data points observed in this publication emphasizing the following:
- Speed: 12-minute median groin puncture to clot contact time and 17-minute median groin puncture to recanalization time.
- Efficacy: 75% First Pass mTICI≥2b using SOFIA 6F.
- Safety: 0% embolization to new territories and symptomatic intracranial hemorrhage rate within 24h.
- Clinical Outcomes: 66.7% of patients experienced good functional outcomes at 90 days.
Please reference the publication for a comprehensive set of data points and outcomes.
“The efficacy and safety data from this prospective, multi-center, independent core-lab adjudicated SOFAST study are very impressive and sets a new innovation standard. High rates of mTICI≥2b (97.2%) revascularization at the procedure end, 70.4% rate of mTICI 2c or better after the first pass, median time to recanalization of 17 minutes and 66.7% rate of good clinical outcomes are amongst the very best metrics reported with contemporary thrombectomy devices,” said Dr. Dheeraj Gandhi, Vice Chairman for Academic Affairs; Director, Interventional Neuroradiology; Director, CMIT Center (Center for Metabolic Imaging and Therapeutics); Professor of Radiology, Neurology and Neurosurgery, University of Maryland School of Medicine.
“The SOFAST Study further underscores that our SOFIA™ Aspiration Catheters have set the standard for more than a decade with its renowned trackability, speed and now with further proven clinical performance,” said Carsten Schroeder, President and CEO, MicroVention, Inc. “We will continue to participate in critical clinical research such as SOFAST, work side-by-side with leading physicians around the world to identify the evolving needs in patient care, and then transform those insights into innovative technologies that help to save patient lives.”
MicroVention also recently celebrated a decade of legacy innovation commemorating the anniversary of SOFIA™ and SOFIA™ Flow Plus Aspiration Catheters, with more than half a million worldwide procedures performed across 170 countries, and 30+ articles published globally since it was first introduced more than ten years ago. Designed for speed to target, clot engagement, kink resistance and a confident first pass, SOFIA Flow Plus Aspiration Catheters continue to set the pace in treating acute ischemic stroke.
From access to revascularization, MicroVention now offers a fully integrated and streamlined portfolio of stroke solutions including SOFIA™, SOFIA™ Flow Plus Aspiration Catheters, as well as ERIC™ Retrieval Device, BOBBY™ Balloon Guide Catheter, WEDGE™ Microcatheter, HEADWAY™ Microcatheters and TRAXCESS™ Guidewires.
About MicroVention, Inc.
Founded in 1997, MicroVention develops and markets medical devices that enable or significantly improve treatment of cerebrovascular diseases. In 2006, Terumo Corporation, a major worldwide medical device company headquartered in Tokyo, Japan, acquired MicroVention into their family of Companies. Terumo’s acquisition of MicroVention allowed both Companies to leverage their unique, proprietary technologies toward an increased focus on treating cerebrovascular diseases. Headquartered in California, MicroVention products are today sold in more than seventy countries through a direct sales organization alongside strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California and San José, Costa Rica. For more information on MicroVention, please visit www.microvention.com.
About Terumo Corporation
Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 Associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large. For more information on Terumo, please visit www.terumo.com/about/profile.
** Editor’s Note: For a Clinical Glossary of Terms, please visit https://www.microvention.com/clinical-education/glossary.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709802645/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celonis Unveils Platform Innovations to Power the AI-Driven, Composable Enterprise4.11.2025 11:00:00 CET | Press release
Celonis, a global leader in Process Intelligence, today at Celosphere 2025 announced major platform innovations that power enterprise AI to reinvent and continuously improve business operations. Daniel Brown, Chief Product Officer at Celonis, emphasized the need for a structured approach to agentic AI. “To truly operationalize AI, you need to identify the right use cases, redesign your business processes, and orchestrate the agents alongside your people and existing systems," Brown said. "Our enhanced capabilities empower our customers and their partners to build AI solutions that lift their operations to unprecedented levels of efficiency and agility.” The Celonis Process Intelligence Platform extracts raw data from systems, applications and devices within and across enterprises. It enriches this data with customers’ unique business context to create a living digital twin of operations—the Process Intelligence Graph. On top of the Graph, the Process Intelligence Platform provides the
Celonis Partners with Databricks to Power Enterprise AI that Continuously Improves Business Operations4.11.2025 11:00:00 CET | Press release
Direct live access to data gives organizations the process-centric context they need to make AI work in the enterprise Celonis, a global leader in Process Intelligence, today announced a partnership with Databricks, the Data and AI company, to provide customers with a seamless, powerful pathway to operationalize AI. The integration leverages Delta Sharing to directly connect the Celonis Process Intelligence Platform with the Databricks Data Intelligence Platform. Delta Sharing is Databricks’ open source approach that enables customers to share live data across platforms, clouds and regions with strong security and governance. This bi-directional integration, powered by Delta Sharing, eliminates the need to move or copy data between the two platforms. It breaks down data silos, reduces data copies, limits synchronization errors, enhances security, and simplifies data governance. With data and process intelligence flowing freely between the two platforms, customers get a continuous learn
Celonis Customers Drive Tangible Business Outcomes with Enterprise AI powered by Process Intelligence4.11.2025 11:00:00 CET | Press release
At Celosphere 2025, Celonis highlighted that 120 “Value Champions” have realized more than $10 million in value each and $8.1 billion in total. Celonis, a global leader in Process Intelligence, today at Celosphere 2025 showcased how leading companies from around the world are reinventing their operations and generating real business results using Enterprise AI, powered by Process Intelligence (PI). "We see so many organizations struggling to get a return on their AI investments,” said Alex Rinke, Celonis co-CEO and co-founder, during his keynote address. “This often happens because they’re thinking about ‘Enterprise AI’ as a technology. In reality, it’s the strategic discipline of infusing AI into every part of their operations. This is what Celonis and our partners help our customers do. We give their AI the context it needs. We guide them to deploy it in the right places. And, we enable them to make it work with everything else they’re doing.” Customer momentum driven by Celonis’ ope
ExtraHop® Expands Presence in EMEA to Meet Enterprise Demand for NDR4.11.2025 10:00:00 CET | Press release
Extends strategic partnership with Ignition Technology to fight modern cyber threats in Northern European markets ExtraHop®, a leader in modern network detection and response (NDR), today announced its expansion into the Nordics and Benelux markets. This strategic move strengthens the company's European footprint on the heels of a period of significant enterprise growth. Following a strong 2024, in which ExtraHop more than doubled its sales to Global 2000 customers in EMEA, the company is bringing its proven momentum to two of the continent's most dynamic markets housing global enterprise headquarters and a thriving ecosystem of world-class tech innovators. To introduce its industry-leading NDR platform to the Nordics and Benelux regions, ExtraHop is extending its distribution agreement with Ignition Technology, a specialist in SaaS-based cybersecurity. Building upon the partnership’s success in the UK and France, the expansion will address growing demand in northern and western Europe
STV to Deploy Post-Quantum’s Secure Communications Platform, Forms Strategic Cooperation to Deliver Next-Generation Security4.11.2025 10:00:00 CET | Press release
STV Group a.s. (“STV”), one of the world’s fastest-growing defence innovators, has signed a multi-year licence agreement to use Post-Quantum’s groundbreaking quantum-safe communications platform and signed a Strategic Cooperation Agreement to accelerate deployment across Europe, NATO, and global defence markets. With quantum computing threatening to render traditional encryption obsolete, the move positions STV at the forefront of the cybersecurity revolution - arming governments, defence forces, and enterprises with next-generation resilience against “Harvest Now, Decrypt Later” attacks. By fusing Post-Quantum’s NATO-tested modular platform with its own world-class defence solutions, STV is setting a new global benchmark for secure communications and digital trust. Together, the two companies are delivering the most advanced, future-proof systems to protect sensitive data and mission-critical operations - ensuring that even in the quantum era, allied communications remain impenetrable
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom